Abstract

Mycoplasma genitalium (MG) is a small bacterium that lives in the epithelium of the urogenital tract and is naturally resistant to many antibiotics due to its structure. The emergence of MG antibiotic resistance to macrolides and fluoroquinolones used for 1st and 2nd line treatment due to widespread testing and treatment of asymptomatic patients is an increasingly serious problem worldwide. In addition the majority of people infected remain asymptomatic and clear infection without developing disease.

To deal with the antimicrobial resistance new guidelines for the management of MG are published in many parts of the world since 2021, where the main keynotes are as follows:
• MG testing is not performed on asymptomatic patients
• All MG-positive specimens should be tested for antimicrobial resistance
• Partners of MG-positive patients should be tested and treated with the same antimicrobial as the index patient
• All patients should attend for a test of cure no sooner than three weeks after the treatment